Diadema Partners LP Celldex Therapeutics, Inc. Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 100,000 shares of CLDX stock, worth $1.94 Million. This represents 1.08% of its overall portfolio holdings.
Number of Shares
100,000Holding current value
$1.94 Million% of portfolio
1.08%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CLDX
# of Institutions
199Shares Held
60.8MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$98.2 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$75.3 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$72.8 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$69 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $907M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...